Samsung Biologics Co.,Ltd., together with its subsidiaries engages in the manufacturing, commercializing, distributing, and selling of biopharmaceuticals products in South Korea, Europe, the United States, and internationally. Its development services include late discovery, cell line development, process development, analytical development, and non-GMP / CGMP manufacturing. The company also offers aseptic filling, lyophilization, finishing, cold chain storage and shipping, and regulatory support services; and quality services and analytical testing services, such as IPC and release testing, stability study and testing, environmental monitoring, biosafety testing, as well as manufactures drug substance. In addition, it engages in the development and manufacture of antibody-drug conjugates and mRNA products. The company was founded in 2011 and is headquartered in Incheon, South Korea.
Frequently asked questions
What sector does Samsung Biologics Co Ltd (207940) operate in?
Samsung Biologics Co Ltd belongs to the Healthcare sector and operates in the Biotechnology industry.
What is Samsung Biologics Co Ltd (207940) current stock price?
As of the latest data, Samsung Biologics Co Ltd stock price is ₩1,564,000, with a previous close of ₩1,549,000. Samsung Biologics Co Ltd gained ₩15,000 in the last trading session, representing a 0.97% increase.
What is Samsung Biologics Co Ltd (207940) current market capitalization?
Samsung Biologics Co Ltd market cap is approximately 72.40 trillion.
Does Samsung Biologics Co Ltd (207940) pay dividends?
No. Samsung Biologics Co Ltd does not pay a dividend.
How did Samsung Biologics Co Ltd (207940) perform in its most recent earnings report?
In the last report (March 31, 2026), Samsung Biologics Co Ltd posted an EPS surprise of 6.32% and a revenue surprise of -2.69%.
When is Samsung Biologics Co Ltd (207940) next earnings report?
Samsung Biologics Co Ltd is expected to release its next earnings report on June 30, 2026.
What is Samsung Biologics Co Ltd (207940) beta (volatility) score?
Samsung Biologics Co Ltd has a beta of 0.214, indicating lower volatility than the overall market.
